{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.4","upperLimit":"10.6","value":"5.9"},{"groupId":"OG001","lowerLimit":"4.2","upperLimit":"13.3","value":"6.4"},{"comment":"upper 95% confidence interval was not achieved due to high censoring rate.","groupId":"OG002","lowerLimit":"5.4","upperLimit":"NA","value":"14.6"},{"comment":"upper 95% confidence interval was not achieved due to high censoring rate.","groupId":"OG003","lowerLimit":"11.8","upperLimit":"NA","value":"26.2"},{"groupId":"OG004","lowerLimit":"2.5","upperLimit":"18.7","value":"6.4"},{"comment":"Median and the upper 95% confidence interval was not achieved due to high censoring rate.","groupId":"OG005","lowerLimit":"13.2","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"27"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"26"}],"units":"Participants"}],"description":"The OS time is defined as the time from baseline to the date of death from any cause. If a participant is not known to have died on or before the date of data cut-off, OS data will be censored on the last date (on or before the cut-off date) the participant was known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with Gastric-GEJ cancer (Second-Third L) received 8 mg/kg ramucirumab given IV on day 1 and 8 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle in Cohort A.\n\nParticipants with Gastric-GEJ cancer (Second-Third L) received 10 mg/kg ramucirumab given IV on day 1 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle in Cohort B.","id":"OG000","title":"Cohort A and B"},{"description":"Participants with BTC cancer (Second-Third L) received 8 mg/kg ramucirumab given IV on day 1 and 8 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.","id":"OG001","title":"Cohort A1"},{"description":"Participants with Gastric-GEJ cancer (First L) received 8 mg/kg ramucirumab given IV on day 1 and 8 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.","id":"OG002","title":"Cohort A2"},{"description":"Participants with NSCLC (Second-Fourth L) received 10 mg/kg ramucirumab given IV on day 1 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.","id":"OG003","title":"Cohort C"},{"description":"Participants with Urothelial cancer (Second-Fourth L) received 10 mg/kg ramucirumab given IV on day 1 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.","id":"OG004","title":"Cohort D"},{"description":"Participants with NSCLC cancer (First L) received 10 mg/kg ramucirumab given IV on day 1 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.","id":"OG005","title":"Cohort E"}],"paramType":"MEDIAN","populationDescription":"All enrolled participants who received at least one dose of the study drug. Censored participants: Cohort A and B = 8; Cohort A1 = 8; Cohort A2 = 12; Cohort C = 12; Cohort D = 6 and Cohort E = 18. Per Protocol, Cohort A and B participants \\[Gastric-GEJ cancer (Second-Third L)\\] were combined and outcome data was analyzed under a single arm (Cohort A and B).","reportingStatus":"POSTED","timeFrame":"Baseline to Death from Any Cause (Up to 24 Months)","title":"Phase 1a and 1b: Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}